Stocks · News reference
Elutia (NASDAQ:ELUT) sells SimpliDerm to Cellution Biologics for up to $11M to boost its balance sheet ahead of the NXT-41x launch.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-21 AccNo: 0001104659-26-099731 Size: 644 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarOn Thursday, Elutia (NASDAQ:ELUT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to
Read original at benzingaFunded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of
Read original at benzingaElutia (NASDAQ:ELUT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the
Read original at benzinga